Sociedade Brasileira de Dermatolodia Surgical & Cosmetic Dermatology


ISSN-e 1984-8773

Volume 2 Number 2

Back to summary


Original Article

Safety and efficacy evaluation of a new hyaluronic acid based filler in the treatment of nasolabial folds and lips outline

Avaliação da segurança e eficácia de novo preenchedor à base de ácido hialurônico no tratamento dos sulcos nasolabiais e contorno dos lábios

Sergio Talarico1, Karime Marques Hassun1, Érica de Oliveira Monteiro1, Meire Odete Brasil Parada1, Laura Bariquelo Buratini1, Lúcia Arruda1, Ediléia Bagatin1

Associate Professor at the Departament of
Dermatology, São Paulo State Federal
University (Unifesp) – São Paulo (SP), Brazil1, Physician, São Paulo State Federal
University (Unifesp) – São Paulo (SP), Brazil2, Collaborating Physician, São Paulo State
Federal University (Unifesp) – São Paulo
(SP), Brazil3, Collaborating Physician, Discipline of
Dermatology, São Paulo State Federal
University (Unifesp) – Botucatu (SP), Brazil4, Head of the Dermatology Service,
Pontifical Catholic University of Campinas
(Puccamp) – Campinas (SP), Brazil5

Received on: 12/03/2010
Approved on: 15/04/2010
This study was conducted at the Federal
University of São Paulo (Unifesp) – São Paulo
(SP), Brazil.
Conflicts of interest: none
Financial support: none



Introduction: The use of dermal filling techniques for soft tissue augmentation has greatly increased in recent years.Hyaluronic acid is one of the most used temporary dermal fillers in the treatment of facial wrinkles, furrows, and folds due to its effectiveness and safety. Objective: To evaluate the efficacy and safety of Perfectha®, a new hyaluronic acid filler, for nasolabial folds and lip correction. Methods: Open, multicenter study comprising 87 women. Efficacy was evaluated by the Global Aesthetic Improvement Scale and the Wrinkle Severity Rating Scale. Safety was evaluated through observation and the reporting of side effects. Results: One week after the injection of the filler, improvement in nasolabial folds and lips was observed in 86% and 89% of the women,respectively. Mild or moderate transient inflammatory reaction and ecchymoses occurred in 15% and 9% of patients, respectively, mainly in nasolabial folds. Two patients presented labial herpes simplex after treatment of the lips.The good results were maintained in 76% and 57% of women for nasolabial folds and in 72% and 45% of women for lips after 3 and 6 months, respectively. Conclusion: Perfectha® was effective and safe for these indications.



The search for non-invasive methods, as well as for new technologies, drugs and other products for correcting cutaneous alterations linked to the aging process is an increasingly significant trend. The technique of dermal filling is among the most used non- surgical procedures and when implemented with hyaluronic acid (HA) ranks second among the five more frequently procedures performed in the United States.1 Dermal fillers containing HA are the filler of choice for correcting wrinkles, folds, depressions, acne scars, improving the outline and volume of the lips, and replacing facial volume. Multiple products, with varying physical and chemical features – and resulting effects – are available.2 Several products are registered and approved for usage in Brazil, raising the importance of verifying the availability of clinical studies and following up the information released by pharmacovigilance in order to assure their efficacy and, more importantly, their safety. The efficacy of HA has been already demonstrated in several studies.3,4 The adverse effects are classified in immediate and delayed, and can vary from ecchymose, light oedema and erythema, and even necrosis.The immediate reaction to the application of HA usually consists of foreseeable light inflammation that can vary in intensity and duration, depending on the product, application technique, asepsis care and individual immunological response.5-8


To evaluate the efficacy and safety of the HA based filler Perfectha®, following the application in the nasolabial folds and labial outline.


This was an open, multicenter study of a therapeutic intervention, conducted at the Federal University of São Paulo – Unifesp, the University of the State of São Paulo/Botucatu Campus – Unesp, and Pontifical Catholic University of Campinas – Puccamp. Following approval by the Committee of Ethics in Research of Unifesp/HSP, women who met the inclusion and exclusion criteria and signed the term of free and informed consent were included. The inclusion criteria were: healthy women, between 20 and 50 years old, with an indication for filling the nasolabial folds and lips.The exclusion criteria were: the use of medication that could interfere with coagulation (acetylsalicylic acid, anticoagulant, gingko biloba, and vitamin E), a history of hypersensitivity or allergy to any component of the product, lesion in the place of application, presence of autoimmune illnesses, pregnancy or breastfeeding and a history of implants in the area.

The product applied was Perfectha® (ObvieLine 8, Chemin du Jubin – 69570 Dardilly, France), which contains HA of non-animal source, with low concentration of protein residues (< 0.25% £gg/ml). The product was approved for commercialization in Brazil by the Brazilian National Agency of Sanitary Surveillance – Anvisa in 2005. The product is stabilized with cross-links made with the 1.4-butanediol diglycidyl ether. Perfectha Derm® in its 24mg/g concentration was used.

Patients received, in a single visit, injections of 1 ml on each side of the nasolabial folds, and 1 ml in the superior and inferior labial outline, with a 27G needle. Retrograde linear injections were administered in the medium dermis after the application of topical anesthesia with a eutectic blend of lidocaine and prilocaine in equal parts. The patients were instructed not to manipulate the area, not to use makeup during the first 24 hours, not to expose to the sun or excessive heat, to use SPF 30 sunscreen daily, and not to carry out sport activities during the week of the application. No other treatment was performed during the study.

The clinical efficacy evaluation – i.e., assessing the correction of the nasolabial folds and the improvement of the outline of the lips – was conducted using the patients'''''''' and investigators’ opinions and pictures obtained on the day of the injection, one hour after and, seven, 30, 60, 90 and 180 days after. The pictures were analyzed by two independent dermatologists using the Global Aesthetic Improvement Scale (GAIS)4 and the Wrinkle Severity Rating Scale (WSRS) 9, described below. Safety was evaluated by the observation and report of immediate and/or delayed, light, moderate or serious adverse events such as erythema, edema, ecchymose, visible nodules and/or palpable and other unexpected symptoms.


Women between the ages of 39 and 49 (n=87) were treated. Of these, 58 and 29 received filler in the nasolabial folds and lips, respectively. One week after treatment, “much improved” and “very much improved” appearances were observed in 86% of patients. The adverse events occurred as follows: inflammatory reaction characterized by light or moderate and transient erythema and edema in 25% of patients, mainly in the nasolabial folds; ecchymoses in 9% of patients; and herpes simplex in two patients following the filling of the lips. The highly satisfactory and excellent results in the nasolabial folds remained in 76% and 57%, and in the lips in 72% and 45% of the women, after three and six months, respectively (Tables 1 and 2 ; Graphics 1 and 2).


This study showed that the filler Perfectha Derm® was effective and safe for nasolabial fold corrections and application in the lips; it improved the outline and increased the volume. The duration of the effect was comparable with that of other temporary fillers.10 The possibility of lengthening the effect, even if only partially has been discussed: this would be caused by stimulating the fibroblasts by the mechanical action of the filler and not by cellular interactions and the production of new collagen tissue.11 The intensity of the inflammatory reaction varied from light to moderate, beginning soon after application and ending spontaneously up to seven days later.These reactions are comparable to similar studies in the literature, which report inflammation ranging from one to two days12 up to eight days.13 Serious adverse events are more frequently described in association with the use of permanent fillers.8 Notwithstanding, some studies report delayed and serious undesirable reactions related to HA.14 Many variables can influence the occurrence and permanence of the inflammatory process, including differences in the properties of the several HA-based fillers, application technique, depth of the injection, individual sensibility and differences in the studied populations. It has been suggested that the protein residues that cannot be totally eliminated during the manufacturing process may be the cause of the inflammatory process, the formation of granulomas, the production of antibodies and the hypersensitivity reactions.15 In this study, no type of delayed reaction was observed. In order to obtain good results without serious complications, it is important that the physician is able to recommend the appropriate procedure, select the patient judiciously, know the chosen product well, and master the application technique.Additionally, the physician must be aware of possible complications and know how to recognize and treat them quickly and effectively.16


The new HA-based product Perfectha Derm® was shown to be effective and safe for the correction of nasolabial folds and the improvement of lips outline and volume in adult women. Immediate reactions were foreseeable and mild, and results lasted up to 180 days after application.


1 . Sagrillo DP. Emerging trends with dermal fillers. Plast Surg Nurs. 2008; 28(3):152-3.

2 . Tezel A, Fredrickson GH. The science of hialuronic acid dermal fillers. J Cosmet Laser Ther. 2008; 10(1):35-42.

3 . DeLorenzi C,Weinberg M, Solish N, Swift A. A multicenter study of the efficacy and safety of subcutaneous nonanimal stabilized hyaluronic acid in aesthetic facial contouring: Interim Report. Dermatol Surg. 2006;32(2): 205-11.

4 . Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double bind, multicenter comparision of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg. 2003; 29(6):588-95.

5 . Gladstone HB, Cohen JL. Adverse effects when injecting facial fillers. Semin Cutan Med Surg. 2007; 26(1):34-9.

6 . Dadzie OE, Mahalingam M, Parada M, El Helou T, Philips T, Bhawan J. Adverse cutaneous reactions to soft tissue fillers - a review of the histological features. J Cutan Pathol. 2008: 35(6):536-48.

7 . Lowe NJ, Maxwell CA, Lowe P, Duick MG, Shah K. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol. 2001; 45(6):930-3.

8 . Parada MB,Michalany NS, Hassun KM, Bagatin E, Talarico S, A histologic study of adverse effects of different cosmetic skin fillers. SkinMed.2005; 4(6):345-9.

9 . Day DJ, Littler CM, Swift RW Gottlieb S. The wrinkle severity rating scale - a validation study. . Am J Clin Dermatol. 2004; 5(1):49-52.

10 . Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg. 2003; 27(5):354-66.

11 . Wang F, Garza LA, Kang S, Varani J, Orringer JS, Finger GJ, et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol. 2007; 143(2):155-63.

12 . Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg. 1998;24(12): 1317-25.

13 . Micheels P. Human anti-hyaluronic acid antibodies: is it possible? Dermatol Surg. 2002; 28(4):359-60.

14 . Pinheiro MVB, Bagatin E, Hassun KM, Talarico S. Adverse Effect of Soft Tissue Augmentation with Hyaluronic Acid. Original Contributions. J Cosmet Dermatol. 2005; 4(3):184-6.

15 . Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation.Dermatol Surg. 2002; 28(6):491-4.

16 . Cohen JL. Understanding, avoiding and managing dermal filler complications.Dermatol Surg. 2008; 34(Suppl 1):S92-S99.

Facebook Twitter Linkedin

© 2021 Sociedade Brasileira de Dermatologia - Todos os direitos reservados

GN1 - Sistemas e Publicações